In an exclusive interview with Biotech Info (in French), Stanislas Veillet, CEO & co-founder of Biophytis, unveils the capital increase for Sarconeos (BIO101) targeting severe COVID-19 & sarcopenia.
With Phase 3 trials in sight, shareholders are invited to join this pivotal phase.